AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00776438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion, influenza vaccine
Description: 0.1 mL, Intradermal
Study NCT00776438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion, influenza vaccine
Description: 0.5 mL, Intramuscular
Study NCT00776438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL, Intradermal
Study NCT00776438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.5 mL, Intramuscular
Study NCT03296410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 and two measles attenuated live vaccine
Description: infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
Study NCT03296410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 and attenuated Japanese encephalitis vaccine
Description: infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
Study NCT03296410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: two measles attenuated live vaccine
Description: infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
Study NCT03296410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: live attenuated Japanese encephalitis vaccine
Description: infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
Study NCT03296410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 vaccine
Description: infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
Study NCT01832792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face self-help
Description: Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
Study NCT01832792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-mail self-help
Description: Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
Study NCT01832792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List
Description: Waiting list condition - participants assigned to a waiting list (no intervention) condition
Study NCT05127083 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Patients will be treated with localized PBM with a diode laser
Description: Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
Study NCT05127083 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be treated with localized PBM with a diode laser
Description: Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
Study NCT05127083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Patients will be treated with localized PBM with a diode laser
Description: Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
Study NCT04485247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transumbilical Laparoscopic-Assisted Appendectomy
Description: appendectomy performed extracorporeally through umbilical port
Study NCT04485247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-port laparoscopic appendectomy
Description: appendectomy performed intracorporeally with 3-port
Study NCT01328301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speed-stable treadmill training
Description: Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
Study NCT00281619 — intervention group
Intervention type: DRUG
Intervention: CellCept (mycophenolate mofetil)
Study NCT00281619 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary Monitoring
Study NCT00281619 — intervention group
Intervention type: BEHAVIORAL
Intervention: Drug Diary
Study NCT00281619 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sampling
Study NCT00832078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SpeediCath Compact Male
Description: CH 12 hydrophilic coated intermitten compact catheter
Study NCT00832078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Speedicath
Description: CH 12 hydrophilic coated intermittent coated catheter
Study NCT00996866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
Study NCT00996866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
Study NCT02304731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Incremental running
Study NCT01307904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Each healthy and Diabetic volunteers received 50 grams of glucose
Study NCT01307904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dates
Description: Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
Study NCT01312883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral education intervention
Description: One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
Study NCT02466815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Current Clinical Formulation (G-018)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
Study NCT02466815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation I (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
Study NCT02466815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation II (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
Study NCT01692925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
Study NCT01692925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
Study NCT04009278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self compression arm
Description: The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
Study NCT00567658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole or Nexium 40 mg BID is given for four months.
Study NCT00567658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole or Nexium 40 mg BID is given for four months.
Study NCT04657198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine (GSK3844766A)
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
Study NCT01586923 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion
Description: RBC transfusion of different storage age
Study NCT04105218 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
Study NCT04105218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
Study NCT00362986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunscreen
Study NCT00362986 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01109953 — intervention group
Intervention type: OTHER
Intervention: Breath-Hold PET/CT image set
Description: In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
Study NCT05893251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Within the manual therapy protocol carried out in the experimental group, we performed a series of passive maneuvers. The patient remains in supine position on a treatment table throughout the treatment, while the therapist sits at the head of the patient on a stool. The sequence of application is as follows:~Suboccipital inhibition technique Cervical spinal mobilization Posterior fascia stretching
Study NCT05893251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural exercises
Description: The treatment plan includes active postural exercises for the cervical spine.
Study NCT03303456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application - Ginger.io
Description: the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
Study NCT03518762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI)
Description: SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
Study NCT03518762 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
Study NCT03518762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
Study NCT03046667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barley β-glucan
Description: The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
Study NCT03046667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
Study NCT03981484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: single dose of 25 IU/kg of 4-PCC at time of enrollment
Study NCT03981484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood, Plasma, Packed Red Blood Cells
Description: site's standard resuscitation protocol
Study NCT02256215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01826227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Study NCT01826227 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro-2-deoxy-D-lucose
Study NCT01826227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Study NCT02204995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy with LRTI
Description: Trapeziectomy with Ligament Reconstruction and Tendon Interposition
Study NCT02204995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy
Description: Trapeziectomy
Study NCT00765843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthoses
Description: orthoses are provided for use in standardized shoes that all subjects receive
Study NCT00765843 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: orthoses
Description: orthoses are provided for use in standardized shoes that all subjects receive
Study NCT03894852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR and cytogenetics
Description: detection of SRSF2 gene mutation and cytogenetic studies
Study NCT05736081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant
Description: Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
Study NCT01038557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBC units
Description: When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
Study NCT01038557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC units
Description: When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
Study NCT01741857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord derived MSC transplantation for SLE
Study NCT03244956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg daily for a maximum of 6 weeks of treatment
Study NCT05198024 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition knowledge
Description: Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
Study NCT05198024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition knowledge
Description: Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
Study NCT03244956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150mg twice daily
Study NCT03244956 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I
Description: 5.5 GBq
Study NCT03221634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03221634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: IV infusion
Study NCT03244956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: 0.9mg on two consecutive days after 35 days of treatment
Study NCT04676191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepiz One+
Description: Simultaneous sleep study with polysomnography and Sleepiz One+
Study NCT04676191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Simultaneous sleep study with polysomnography and Sleepiz One+
Study NCT01923246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single WEB intervention
Description: Brief WEB intervention recieved once
Study NCT01923246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated WEB intervention
Description: WEB intervention recieved twice.
Study NCT01923246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single IVR intervention
Description: IVR intervention recieved once
Study NCT01923246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated IVR intervention
Description: IVR intervention recieved twice
Study NCT01720186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT 4D imaging in a synchronized mode centered on the thorax.
Study NCT01720186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT 4D imaging in a synchronized mode centered on the thorax.
Study NCT00225199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visanne (BAY86-5258, SH T00660AA)
Description: orally once daily
Study NCT00225199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once daily
Study NCT02001779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary SEMS loaded with 125I seeds
Description: A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
Study NCT02001779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional biliary SEMS
Description: A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
Study NCT00760383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
Study NCT00760383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
Study NCT00947427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab (anti IL-1beta)
Description: canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
Study NCT00947427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injections
Study NCT02957279 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: In the sepsis group, antibiotics were used when needed.
Study NCT00704223 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation